hotspot -WSS

hotspot

author：comprehensive 2025-09-27 23:53:42 - browse：238

Chris O'Meara/AP

Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Color Health wants to make cancer screenings convenient

explore

WSS

Neuroscience renaissance leads to new crop of psychiatric drugs

Inequities make cancer less preventable for women: report

Inequities make cancer less preventable for women: report

Mindstrong's demise and the future of mental health care

Neuroscience renaissance leads to new crop of psychiatric drugs

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

focus

hotspot

hotspot

Jerome Adams on the need for new antivirals for Covid

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Malaria cases in Florida and Texas: Here’s what you need to know

Doctor of U.S. President Joe Biden says he is fit for duty

Hepatitis C has a cure — but many Americans still lack access to it

Doctor of U.S. President Joe Biden says he is fit for duty

Apple is now the first public company to be valued at $3 trillion

Would Medicare drug price negotiations stall in a shutdown?

Tori Bowie and the unacceptable rates of Black maternal death

Medicare isn't yet testing food as medicine

hotspot

Medicare isn't yet testing food as medicine

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Children’s Hospital revives plan for pedestrian bridge

Redefining sustainability for the pharmaceutical industry

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

How one patient went off dialysis — and others can too

explore

focus

focus

Wikipedia